))
DME/Retina Edition: Top Headlines for Week of June 3, 2024
Manage episode 422229053 series 3560281
Conteúdo fornecido por Healio. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Healio ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
In this edition, AI model helps predict anti-VEGF response in DME, Merck to acquire EyeBio and more. Read the full coverage here:
VIDEO: AI model helps predict anti-VEGF response in diabetic macular edema
VIDEO: IOP remains stable up to 48 weeks with aflibercept 8 mg for DME
Phase 2 study of potential DME oral therapy meets primary endpoints
FDA approves aflibercept biosimilars Yesafili, Opuviz
References:
Barakat MR. Intraocular pressure outcomes with intravitreal injection of aflibercept 8 mg and 2 mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.
Luvisi J. Using a convolutional neural network to predict response of diabetic macular edema to intravitreal anti-vascular endothelial growth factor. Presented at: Kiawah Eye; May 30-June 1, 2024; Kiawah Island, South Carolina.
119 episódios
Compartilhar
